Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.
Key Details
- 1Neuropacs Corp. developed an AI-enabled MRI software targeting neurodegenerative disease evaluation.
- 2The tool differentiates between Parkinson’s disease, atypical parkinsonism, multiple system atrophy Parkinsonian variant, and progressive supranuclear palsy.
- 3FDA has granted the product De Novo classification, indicating novel technology.
- 4The software quantifies MRI data and aids in more accurate clinical decision-making.
Why It Matters
FDA De Novo clearance validates the clinical utility of this MRI-based AI tool, potentially supporting radiologists in systematizing diagnosis of challenging neurodegenerative syndromes. This may lead to more precise patient management and sets a precedent for AI-driven neuroimaging diagnostics.
Source
Radiology Business
Related News
•AuntMinnie
Radiology and AI Poised to Transform Endometriosis Diagnosis
Advances in imaging and AI are improving early detection and management of endometriosis.
•Radiology Business
Aidoc Raises $150M to Expand Imaging AI Portfolio and Global Reach
Aidoc secures $150M in Series E funding led by Goldman Sachs to accelerate expansion of its clinical AI platform.
•AuntMinnie
AI-Driven Mammogram Analysis Boosts Cardiovascular Risk Prediction in Women
AI quantification of breast arterial calcifications (BACs) on mammograms enhances prediction of cardiovascular events beyond traditional risk models.